Carbiotix adds three new LinkGut customers in Q3

Carbiotix (publ) ("Carbiotix" or "Company") announces today that the Company has acquired three new LinkGut customers during the third quarter. Since the launch as a B2B white label microbiome testing service in 2021, LinkGut has grown thanks to early feedback from customers, with interest continuing to expand within the nutraceutical, cosmetic, and health and wellness sectors.

Today, Carbiotix is pleased to announce that the Company has expanded its customer base with three new LinkGut customers in the last quarter, underlining the continued growth and demand for the service. Carbiotix's ambition is to offer a cost-effective, flexible, and reliable B2B white label consumer microbiome testing service. This message appears to have resonated well with the market, reflected in the increased customer base and growing number of customer inquiries.

Carbiotix is now working together with the new customers to establish their services, and expects an increase in order volume, similar to the growth seen with previous customers. The increased demand for the LinkGut service opens up opportunities for future sales of the CarbiAXOS product, as some LinkGut customers currently offer or intend to offer prebiotic-based products. By being able to validate the effects of CarbiAXOS or another prebiotic-based product with the help of LinkGut, our customers can counteract the potential declining interest of individuals in taking a product over a longer period. Through results from LinkGut, our customers can provide personalised recommendations to individuals through changes to e.g. dosage or product. This enables personalisation and better allocation of health resources, which in turn can build loyalty and increase sales.

Going forward, Carbiotix intends to continue to ramp up marketing activities related to the LinkGut service towards both established companies and startups. With the increasing interest and usage of the LinkGut service within clinical and research applications, the Company views this as an important market to target moving forward. Key trends such as transparency and personalisation within the microbiome health industry continue to grow, and Carbiotix believes that LinkGut is well-positioned to meet and accelerate these trends.

Erik Deaner, CEO of Carbiotix, comments:
"We are excited to welcome two new customers to our LinkGut service, who exemplify the type of customer we wish to attract as they represent potential customers for our CarbiAXOS product and have already expressed interest in it. Both customers are active in the dietary supplement market with a focus on gastrointestinal health; one specialised in athletes and the other with a broader focus on gastrointestinal health. Our third new LinkGut customer has chosen us to support the treatment of children and adolescents struggling with everything from learning difficulties to weight issues. It makes me proud that we have managed to double our customer base in a single quarter, a success that will be reflected in Carbiotix's revenue moving forward. The market's positive response is encouraging and we are keen to continue delivering services that meet our customers' needs. The synergies between LinkGut and CarbiAXOS enable an optimal allocation of health resources and strengthen our position within the microbiome health industry.”

Forward-looking statements
This communication contains forward-looking statements, consisting of subjective assumptions and forecasts for future scenarios. Predictions for the future only apply as of the date they are made and are, by their nature, as is research and development work in the biotechnology segment, associated with risk and uncertainty. With this in mind, the actual outcome may deviate significantly from the scenarios as described in this press release.

For further information:
Carbiotix AB
Erik Deaner, CEO
Tel: +46 (0)738 67 30 85
E-mail: erik.deaner@carbiotix.com

Carbiotix AB (CRBX) (www.carbiotix.com) is an award-winning biotechnology company pioneering microbiome healthcare through a portfolio of prebiotic modulators and diagnostic testing services.